AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo
Anna Brown / endpoints - The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...
AI Summary: AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market.
World Cancer Day: A Global Call to Awareness and Action 2026, Part 2
oncodaily - World Cancer Day is observed annually on February 4 and was established in 2000 at the World Summit Against Cancer for the New Millennium in Paris. The initiative was led […]
AI Summary: World Cancer Day 2026, observed on February 4, serves as a global rallying cry to boost cancer awareness, promote early detection, and improve patient access to care. Healthcare professionals, advocates, and patients united at the event to spotlight the critical need for innovation and coordinated action against cancer.
- Early Detection & Access Initiatives (4)
- Other Cancer News (15)
- Research and Treatment Advances (28)
- World Cancer Day Global Events (4)
- All Other Stories
Early Detection & Access Initiatives
Other Cancer News
Research and Treatment Advances
World Cancer Day Global Events
All Other Stories
HHS to drop 340B rebate pilot after court rulings
Ella Jeffries / beckershospitalreview - HHS will drop its 340B rebate model pilot program following two federal court rulings that blocked its implementation. The program, announced in August 2025, was challenged by the American Hospital Association, the Maine Hospital Association and four safe…
AI Summary: In a twist that no one saw coming (except the federal courts), HHS has scrapped its controversial 340B rebate pilot after two judicial rulings blocked its implementation. Providers, relieved to avoid a potential cash flow nightmare, are quietly celebrating the decision as one less bureaucratic headache to manage.
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...
AI Summary: Bayer’s latest Phase 3 study of asundexian has shown a 26% reduction in secondary ischemic stroke risk—without an increased bleeding risk. This compelling data bolsters the drug’s prospects as a blockbuster in stroke prevention and underscores Bayer’s commitment to advancing cardiovascular therapies.
Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery
oncodaily - Eikon Therapeutics has raised $381 million through its IPO, pricing at the top of its range in a strong sign of renewed investor appetite for biotech offerings. The South San […]
AI Summary: Eikon Therapeutics successfully raised $381 million in its IPO, reinforcing investor confidence in novel biotechnology approaches for cancer drug discovery. The fundraising milestone is expected to accelerate live‐cell imaging and other innovative oncology research initiatives.
HHS scraps 340B rebate pilot in win for hospitals
Emily Olsen / healthcaredive - The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates on some drugs instead of upfront discounts.
AI Summary: Federal health officials have reversed course on a highly controversial 340B rebate pilot program after federal courts blocked its implementation – a move hailed by providers as a long‐awaited relief from cash flow and administrative burdens.
Statin pills much safer than advertised, major review finds
bbc - The results, in The Lancet journal, come from trials involving more than 120,000 people comparing statins with a dummy drug or placebo.
AI Summary: Multiple large‐scale analyses have debunked the long‐held worries about statin side effects – it turns out that those pesky symptoms listed on package leaflets are no more common than when taking a placebo. In other words, patients can keep calm and lower cholesterol with confidence.
Novo Nordisk vows legal action to protect Wegovy pill
medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
AI Summary: Novo Nordisk has vowed to take legal action after discovering that competitors – including Hims & Hers – plan to market a compounded, lower‐priced version of its new Wegovy weight‐loss pill. The company is mobilizing its legal team to protect its intellectual property amid fierce market competition.
FTC deal over insulin prices forces Express Scripts to overhaul policies
Elizabeth Casolo / beckershospitalreview - The Federal Trade Commission reached a settlement with Cigna’s Express Scripts in a case over alleged inflation of insulin prices, according to a Feb. 4 agency news release. Under the settlement, Express Scripts must keep drug manufacturer compensation de…
AI Summary: Federal regulators reached a settlement with Express Scripts amid long‐standing allegations that the pharmacy benefit manager overcharged for insulin. The deal forces sweeping policy revisions to curb price inflation and protect patients from rising costs, following years of regulatory scrutiny over insulin rebate practices.
Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade
Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…
AI Summary: Summit Therapeutics announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for Ivonescimab—intended for patients with EGFR‑mutated non‑small cell lung cancer who have progressed after TKI therapy. The regulatory nod signals a promising step forward in targeted lung cancer treatment.
FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia
AI Summary: U.S. regulators have just cleared Intellia Therapeutics’ Phase 3 study of a gene‐editing therapy intended to treat a genetic nerve disorder, effectively rescinding a clinical hold. This development opens the door to renewed patient enrolment and further evaluation of the treatment’s safety and effectiveness.
‘Vertical integration is destroying people’s ability to access care’: Payer CEOs face bipartisan congressional grilling
Jakob Emerson / beckershospitalreview - The CEOs of the nation’s largest health insurers drew the ire of lawmakers on both sides of the aisle during congressional hearings Jan. 22 over industry consolidation, prior authorization practices and executive pay, with members pressing executives to e…
AI Summary: Lawmakers grilled top health insurance executives in a high‐profile congressional hearing over rising healthcare costs, vertical integration and shifting of cost burdens to hospitals and drug makers. The grilling highlighted deep concerns over patient access and systemic inefficiencies in American healthcare.
#JPM26: Day 3 at the JP Morgan Healthcare Conference
ENDPOINTS / endpoints - It’s Wednesday at the JP Morgan Healthcare Conference, and as the sessions wind down, we’ll be keeping an eye on presentations from WuXi AppTec and AbbVie. Yesterday afternoon, our Executive Editor Drew Armstrong spoke with ...
AI Summary: At the JP Morgan Healthcare Conference 2026, top industry leaders unveiled transformative developments—from embedding AI into EHR systems to discussions on GLP‐1 compounding innovations and strategic Q&A sessions with leading pharma CEOs. The event provided a broad overview of emerging trends in healthcare technology and innovation.
F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds
Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.
AI Summary: New in‑depth analyses of internal FDA documents reveal that regulatory decisions on the abortion pill mifepristone were firmly based on thorough evidence rather than political pressure, dispelling common misconceptions about politicized review processes.
#JPM26: Day 1 at the JP Morgan Healthcare Conference
ENDPOINTS / endpoints - It’s day 1 at the JP Morgan Healthcare Conference, and the mood heading into the week is one of cautious optimism. Biotech fundraising was off to a hot start in 2026. There ...
AI Summary: At the 2026 JP Morgan Healthcare Conference, several industry leaders showcased cutting‐edge sessions. Presentations covered AI enhancements in EHRs, real‑time prior authorization solutions, and strategic partnerships from major players including Moderna, Elation Health, and CommonSpirit, reflecting finance–tech convergence in healthcare innovation.
No Link Between Acetaminophen in Pregnancy and Autism, a New Study Finds
Azeen Ghorayshi / nytimes - The review looked at more than three dozen studies and found no evidence that acetaminophen increased the risk of neurodevelopmental disorders in children.
AI Summary: A new comprehensive review of more than three dozen studies found no evidence that taking acetaminophen during pregnancy increases the risk of neurodevelopmental disorders such as autism, ADHD or intellectual disabilities. Despite lingering public anxiety and the occasional skeptical quip, expectant mothers can take a breath of relief.
Life-extending prostate cancer drug to be offered to thousands in England
bbc - Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.
AI Summary: Health authorities in England have announced that nearly 7,000 additional men with hormone‐sensitive prostate cancer will soon be eligible for abiraterone—a breakthrough treatment that extends survival. The drug is expected to be available within weeks, marking a significant step forward in targeted prostate cancer care.
FDA rejects cancer therapy for rare post-transplant disease
Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …
AI Summary: The FDA has again rejected Atara’s cell therapy aimed at treating rare post‐transplant complications linked to Epstein–Barr virus. Despite high hopes for this innovative approach, regulatory concerns remain over its safety and efficacy—clearly a “repeat performance” in the world of breakthrough therapies.
Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access
Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…
AI Summary: A compounding pharmacy has taken legal aim at industry giants Eli Lilly and Novo Nordisk, alleging an anti‑competitive scheme designed to restrict access to their blockbuster GLP‑1 therapies. The lawsuit puts the pharmaceutical titans on the defensive as antitrust concerns mix with therapeutic access debates.
NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery
oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]
AI Summary: Eli Lilly and Nvidia have teamed up to invest up to $1 billion in a brand‑new AI lab aimed at reinventing drug discovery. This collaborative venture promises to streamline R&D with cutting‑edge artificial intelligence while hinting that pharma’s reliance on tech is evolving – and it’s not all sci‑fi smoke and mirrors.